Literature DB >> 21877234

Health care disparities in the acute management of venous thromboembolism based on insurance status in the U.S.

Gregory J Misky1, Jonathan C Manheim, Nichole Zehnder, Vicky Nguyen, Paul F Swenson, Patrick Klem, Toby Trujillo, M A Earnest.   

Abstract

Acute venous thromboembolism (VTE) is common, costly, and potentially lethal. Therapeutic anticoagulation requires timely, closely monitored medical follow-up. If ineffective, clinical outcomes worsen and resource utilization increases. This risk may be magnified in uninsured patients. This study examined VTE care in hospital patients and investigated differences based on insurance status. We performed a retrospective chart review on medical VTE patients at an academic teaching hospital between December 1, 2007 and April 30, 2009. We reviewed medical records for demographics, insurance, admission status, length of stay (LOS), and 30-day Emergency Department (ED) recidivism and hospital readmission. Measured outcomes were analyzed based on payer source. We identified 234 medical VTE patients; 67 patients were uninsured (28.6%). 106 patients (45.3%) presented with deep vein thrombosis only. Most VTE patients were admitted to the hospital (171; 73.1%), including all 128 pulmonary embolism patients. Admitted uninsured patients averaged a LOS of 5.5 versus 3.7 days for insured (P = 0.03), with ED recidivism rates of 26.1 versus 11.3%, respectively (P = 0.02). Average cost for all VTE care in uninsured patients was $12,297 versus $7,758 for insured patients (P = 0.04). This study identified disparities in medical care and resource utilization for medical VTE patients based on insurance. Uninsured VTE patients were hospitalized nearly two additional days and were more than two times as likely to return to the ED within 30 days compared to insured patients. Additional research is needed to explain these disparities, and to explore system improvements for the uninsured VTE patient.

Entities:  

Mesh:

Year:  2011        PMID: 21877234     DOI: 10.1007/s11239-011-0632-3

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  25 in total

1.  Insuring America's health: principles and recommendations.

Authors: 
Journal:  Acad Emerg Med       Date:  2004-04       Impact factor: 3.451

2.  Insurance status and hospital care for myocardial infarction, stroke, and pneumonia.

Authors:  Omar Hasan; E John Orav; LeRoi S Hicks
Journal:  J Hosp Med       Date:  2010-10       Impact factor: 2.960

3.  Insurance status and access to urgent ambulatory care follow-up appointments.

Authors:  Brent R Asplin; Karin V Rhodes; Helen Levy; Nicole Lurie; A Lauren Crain; Bradley P Carlin; Arthur L Kellermann
Journal:  JAMA       Date:  2005-09-14       Impact factor: 56.272

4.  Outpatient follow-up visit and 30-day emergency department visit and readmission in patients hospitalized for chronic obstructive pulmonary disease.

Authors:  Gulshan Sharma; Yong-Fang Kuo; Jean L Freeman; Dong D Zhang; James S Goodwin
Journal:  Arch Intern Med       Date:  2010-10-11

5.  Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.

Authors:  Kevin K Knight; John Wong; Ole Hauch; Gail Wygant; Daniel Aguilar; Joshua J Ofman
Journal:  Value Health       Date:  2005 May-Jun       Impact factor: 5.725

6.  Venous thromboembolic disease: comparison of the diagnostic process in blacks and whites.

Authors:  Paul D Stein; Russell D Hull; Kalpesh C Patel; Ronald E Olson; William A Ghali; Andrew K Alshab; Frederick A Meyers
Journal:  Arch Intern Med       Date:  2003 Aug 11-25

7.  Care denied: US residents who are unable to obtain needed medical services.

Authors:  D U Himmelstein; S Woolhandler
Journal:  Am J Public Health       Date:  1995-03       Impact factor: 9.308

8.  The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence.

Authors:  R D Hull; G E Raskob; R F Brant; G F Pineo; K A Valentine
Journal:  Arch Intern Med       Date:  1997-11-10

9.  Hospital-based costs associated with venous thromboembolism treatment regimens.

Authors:  G Merli; C Ferrufino; J Lin; M Hussein; D Battleman
Journal:  J Thromb Haemost       Date:  2008-07-01       Impact factor: 5.824

10.  Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin.

Authors:  Alex C Spyropoulos; Judith S Hurley; Gabrielle N Ciesla; Gregory de Lissovoy
Journal:  Chest       Date:  2002-07       Impact factor: 9.410

View more
  4 in total

Review 1.  Self-Identified Social Determinants of Health during Transitions of Care in the Medically Underserved: a Narrative Review.

Authors:  Anunta Virapongse; Gregory J Misky
Journal:  J Gen Intern Med       Date:  2018-08-20       Impact factor: 5.128

2.  Factors associated with overcrowded emergency rooms in Thailand: a medical school setting.

Authors:  Arrug Wibulpolprasert; Yuwares Sittichanbuncha; Pungkava Sricharoen; Somporn Borwornsrisuk; Kittisak Sawanyawisuth
Journal:  Emerg Med Int       Date:  2014-09-29       Impact factor: 1.112

3.  American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.

Authors:  Thomas L Ortel; Ignacio Neumann; Walter Ageno; Rebecca Beyth; Nathan P Clark; Adam Cuker; Barbara A Hutten; Michael R Jaff; Veena Manja; Sam Schulman; Caitlin Thurston; Suresh Vedantham; Peter Verhamme; Daniel M Witt; Ivan D Florez; Ariel Izcovich; Robby Nieuwlaat; Stephanie Ross; Holger J Schünemann; Wojtek Wiercioch; Yuan Zhang; Yuqing Zhang
Journal:  Blood Adv       Date:  2020-10-13

4.  Recurrent hospitalization and healthcare resource use among patients with deep vein thrombosis and pulmonary embolism: findings from a multi-payer analysis.

Authors:  Kathleen Lang; Aarti A Patel; Michael Munsell; Brahim K Bookhart; Samir H Mody; Jeff R Schein; Joseph Menzin
Journal:  J Thromb Thrombolysis       Date:  2015-05       Impact factor: 2.300

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.